First Clinical Medical School, Shanxi Medical University, Taiyuan, 030001, China.
Department of Head and Neck Surgery, Shanxi Hospital Affiliated to Cancer Hospital, Shanxi Provincial Cancer Hospital, Chinese Academy of Medical Sciences/Cancer HospitalAffiliated to Shanxi Medical University, Taiyuan, 031000, Shanxi Province, China.
World J Surg Oncol. 2024 Oct 25;22(1):282. doi: 10.1186/s12957-024-03561-9.
To investigate the clinicopathologic characteristics, therapeutic methods, and prognosis of secretory carcinoma of salivary gland (SCSG).
The clinicopathologic data of 13 patients with SCSG admitted to Shanxi Cancer Hospital from January 2018 to June 2023 were retrospectively analyzed, and a literature review was performed.
A total of eight males and five females aged 22-78 years old were enrolled, and they commonly presented with painless masses in the parotid or submandibular gland. They all underwent surgical treatment, accompanied by typical pathological examinations postoperatively. Fluorescence in situ hybridization (FISH) was conducted in seven cases, the results were all positive, and no gene fusion other than ETV6-NTRK3 was found. Two patients developed local relapse during follow-up, both of which were in the surgical area. By the end of the follow-up, 12 patients survived and one patient died.
SCSG is a rare low-grade malignancy with a good prognosis. Pathological and immunohistochemical characteristics are the key to secretory carcinoma (SC) diagnosis, and surgical excision is the major treatment means for SCSG. Whether to perform simultaneous cervical lymph node dissection and other adjuvant therapies should be determined based on the pathological stage and the presence or absence of high-risk factors.
研究涎腺分泌性癌(SCSG)的临床病理特征、治疗方法和预后。
回顾性分析 2018 年 1 月至 2023 年 6 月山西医科大学附属肿瘤医院收治的 13 例 SCSG 患者的临床病理资料,并进行文献复习。
共纳入 8 例男性和 5 例女性患者,年龄 22-78 岁,均以腮腺或颌下腺无痛性肿块就诊。所有患者均接受了手术治疗,术后均伴有典型的病理检查。7 例行荧光原位杂交(FISH)检查,结果均为阳性,未发现除 ETV6-NTRK3 以外的基因融合。2 例患者在随访中出现局部复发,均位于手术区域。随访结束时,12 例患者存活,1 例患者死亡。
SCSG 是一种罕见的低级别恶性肿瘤,预后良好。病理和免疫组织化学特征是 SC 诊断的关键,手术切除是 SCSG 的主要治疗手段。是否行同期颈淋巴结清扫术及其他辅助治疗应根据病理分期和有无高危因素而定。